Journal of Clinical Investigation · 2017 · 47 citations · 32 references
MedicineCancer BiologyOncologyMolecular OncologyTumor MicroenvironmentTumor ProgressionAngiogenesis In CancerBrain TumorsCancer Cell SignalingCancer ProgressionMyeloid-derived Suppressor CellsTumor Suppressor GenesGranulocytic Myeloid-derived Suppressor CellsMalignant ProgressionMyeloid Cell ActivationMyeloid Differentiation SignalingMyeloid NeoplasmsMyeloid-derived Suppressor Cell FunctionSuppressive Myeloid CellsTumor Angiogenic Switch
Tumors are capable of coopting hematopoietic cells to create a suitable microenvironment to support malignant growth. Here, we have demonstrated that upregulation of kinase insert domain receptor (KDR), also known as VEGFR2, in a myeloid cell sublineage is necessary for malignant progression of gliomas in transgenic murine models and is associated with high-grade tumors in patients. KDR expression increased in myeloid cells as myeloid-derived suppressor cells (MDSCs) accumulated, which was associated with the transformation and progression of low-grade fibrillary astrocytoma to high-grade anaplastic gliomas. KDR deficiency in murine BM-derived cells (BMDCs) suppressed the differentiation of myeloid lineages and reduced granulocytic/monocytic populations. The depletion of myeloid-derived KDR compromised its proangiogenic function, which inhibited the angiogenic switch necessary for malignant progression of low-grade to high-grade tumors. We also identified inhibitor of DNA binding protein 2 (ID2) as a key upstream regulator of KDR activation during myeloid differentiation. Deficiency of ID2 in BMDCs led to downregulation of KDR, suppression of proangiogenic myeloid cells, and prevention of low-grade to high-grade transition. Tumor-secreted TGF-β and granulocyte-macrophage CSF (GM-CSF) enhanced the KDR/ID2 signaling axis in BMDCs. Our results suggest that modulation of KDR/ID2 signaling may restrict tumor-associated myeloid cells and could potentially be a therapeutic strategy for preventing transformation of premalignant gliomas.
32
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Zvi G. Fridlender, Jing Sun, Samuel Kim et al. · Cancer Cell · 2009 · 3.3K citations · Full text
Medicine, Immunology, Oncology +12
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Rosandra N. Kaplan, Rebecca D. Riba, Stergios Zacharoulis et al. · Nature · 2005 · 3.2K citations · Full text
Medicine, Cell Biology, Hematology +14
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Bin‐Zhi Qian, Jiufeng Li, Hui Zhang et al. · Nature · 2011 · 2.9K citations · Full text
Medicine, Cancer Biology, Oncology +14